Yeast's Histone H3K56 Juggles Several Important Roles
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Integrative Genomic and Epigenomic Analyses Identified IRAK1 As a Novel Target for Chronic Inflammation-Driven Prostate Tumorigenesis
bioRxiv preprint doi: https://doi.org/10.1101/2021.06.16.447920; this version posted June 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Integrative genomic and epigenomic analyses identified IRAK1 as a novel target for chronic inflammation-driven prostate tumorigenesis Saheed Oluwasina Oseni1,*, Olayinka Adebayo2, Adeyinka Adebayo3, Alexander Kwakye4, Mirjana Pavlovic5, Waseem Asghar5, James Hartmann1, Gregg B. Fields6, and James Kumi-Diaka1 Affiliations 1 Department of Biological Sciences, Florida Atlantic University, Florida, USA 2 Morehouse School of Medicine, Atlanta, Georgia, USA 3 Georgia Institute of Technology, Atlanta, Georgia, USA 4 College of Medicine, Florida Atlantic University, Florida, USA 5 Department of Computer and Electrical Engineering, Florida Atlantic University, Florida, USA 6 Department of Chemistry & Biochemistry and I-HEALTH, Florida Atlantic University, Florida, USA Corresponding Author: [email protected] (S.O.O) Running Title: Chronic inflammation signaling in prostate tumorigenesis bioRxiv preprint doi: https://doi.org/10.1101/2021.06.16.447920; this version posted June 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract The impacts of many inflammatory genes in prostate tumorigenesis remain understudied despite the increasing evidence that associates chronic inflammation with prostate cancer (PCa) initiation, progression, and therapy resistance. -
RFC2 Antibody
Product Datasheet RFC2 Antibody Catalog No: #43122 Orders: [email protected] Description Support: [email protected] Product Name RFC2 Antibody Host Species Rabbit Clonality Polyclonal Purification Antigen affinity purification. Applications WB Species Reactivity Hu Specificity The antibody detects endogenous levels of total RFC2 protein. Immunogen Type peptide Immunogen Description Synthetic peptide of human RFC2 Target Name RFC2 Other Names RFC40 Accession No. Swiss-Prot#: P35250Gene ID: 5982 Calculated MW 39kd Concentration 3.5mg/ml Formulation Rabbit IgG in pH7.4 PBS, 0.05% NaN3, 40% Glycerol. Storage Store at -20°C Application Details Western blotting: 1:200-1:1000 Immunohistochemistry: 1:30-1:150 Images Gel: 10%SDS-PAGE Lysate: 40 µg Lane: Human liver cancer tissue Primary antibody: 1/500 dilution Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution Exposure time: 20 seconds Background This gene encodes a member of the activator 1 small subunits family. The elongation of primed DNA templates by DNA polymerase delta and epsilon requires the action of the accessory proteins, proliferating cell nuclear antigen (PCNA) and replication factor C (RFC). Replication factor C, also called activator 1, is a protein complex consisting of five distinct subunits. This gene encodes the 40 kD subunit, which has been shown to be responsible for binding ATP and may help promote cell survival. Disruption of this gene is associated with Williams syndrome. Alternatively spliced transcript variants Address: 8400 Baltimore Ave., Suite 302, College Park, MD 20740, USA http://www.sabbiotech.com 1 encoding distinct isoforms have been described. A pseudogene of this gene has been defined on chromosome 2. -
Targeting Non-Oncogene Addiction for Cancer Therapy
biomolecules Review Targeting Non-Oncogene Addiction for Cancer Therapy Hae Ryung Chang 1,*,†, Eunyoung Jung 1,†, Soobin Cho 1, Young-Jun Jeon 2 and Yonghwan Kim 1,* 1 Department of Biological Sciences and Research Institute of Women’s Health, Sookmyung Women’s University, Seoul 04310, Korea; [email protected] (E.J.); [email protected] (S.C.) 2 Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Korea; [email protected] * Correspondence: [email protected] (H.R.C.); [email protected] (Y.K.); Tel.: +82-2-710-9552 (H.R.C.); +82-2-710-9552 (Y.K.) † These authors contributed equally. Abstract: While Next-Generation Sequencing (NGS) and technological advances have been useful in identifying genetic profiles of tumorigenesis, novel target proteins and various clinical biomarkers, cancer continues to be a major global health threat. DNA replication, DNA damage response (DDR) and repair, and cell cycle regulation continue to be essential systems in targeted cancer therapies. Although many genes involved in DDR are known to be tumor suppressor genes, cancer cells are often dependent and addicted to these genes, making them excellent therapeutic targets. In this review, genes implicated in DNA replication, DDR, DNA repair, cell cycle regulation are discussed with reference to peptide or small molecule inhibitors which may prove therapeutic in cancer patients. Additionally, the potential of utilizing novel synthetic lethal genes in these pathways is examined, providing possible new targets for future therapeutics. Specifically, we evaluate the potential of TONSL as a novel gene for targeted therapy. Although it is a scaffold protein with no known enzymatic activity, the strategy used for developing PCNA inhibitors can also be utilized to target TONSL. -
Recurrent Herpes Simplex Virus Type 1 (HSV-1) Infection Modulates Neuronal Aging Marks in in Vitro and in Vivo Models
International Journal of Molecular Sciences Article Recurrent Herpes Simplex Virus Type 1 (HSV-1) Infection Modulates Neuronal Aging Marks in In Vitro and In Vivo Models Giorgia Napoletani 1 , Virginia Protto 1 , Maria Elena Marcocci 1 , Lucia Nencioni 1 , Anna Teresa Palamara 1,2,† and Giovanna De Chiara 3,*,† 1 Department of Public Health and Infectious Diseases, Sapienza University of Rome, Laboratory Affiliated to Istituto Pasteur Italia–Fondazione Cenci Bolognetti, 00185 Rome, Italy; [email protected] (G.N.); [email protected] (V.P.); [email protected] (M.E.M.); [email protected] (L.N.); [email protected] (A.T.P.) 2 Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy 3 Institute of Translational Pharmacology, National Research Council (CNR), 00133 Rome, Italy * Correspondence: [email protected] † Co-last authors. Abstract: Herpes simplex virus 1 (HSV-1) is a widespread neurotropic virus establishing a life-long latent infection in neurons with periodic reactivations. Recent studies linked HSV-1 to neurodegen- erative processes related to age-related disorders such as Alzheimer’s disease. Here, we explored whether recurrent HSV-1 infection might accelerate aging in neurons, focusing on peculiar marks of aged cells, such as the increase in histone H4 lysine (K) 16 acetylation (ac) (H4K16ac); the decrease Citation: Napoletani, G.; Protto, V.; of H3K56ac, and the modified expression of Sin3/HDAC1 and HIRA proteins. By exploiting both Marcocci, M.E.; Nencioni, L.; in vitro and in vivo models of recurrent HSV-1 infection, we found a significant increase in H4K16ac, Palamara, A.T.; De Chiara, G. -
Plenary and Platform Abstracts
American Society of Human Genetics 68th Annual Meeting PLENARY AND PLATFORM ABSTRACTS Abstract #'s Tuesday, October 16, 5:30-6:50 pm: 4. Featured Plenary Abstract Session I Hall C #1-#4 Wednesday, October 17, 9:00-10:00 am, Concurrent Platform Session A: 6. Variant Insights from Large Population Datasets Ballroom 20A #5-#8 7. GWAS in Combined Cancer Phenotypes Ballroom 20BC #9-#12 8. Genome-wide Epigenomics and Non-coding Variants Ballroom 20D #13-#16 9. Clonal Mosaicism in Cancer, Alzheimer's Disease, and Healthy Room 6A #17-#20 Tissue 10. Genetics of Behavioral Traits and Diseases Room 6B #21-#24 11. New Frontiers in Computational Genomics Room 6C #25-#28 12. Bone and Muscle: Identifying Causal Genes Room 6D #29-#32 13. Precision Medicine Initiatives: Outcomes and Lessons Learned Room 6E #33-#36 14. Environmental Exposures in Human Traits Room 6F #37-#40 Wednesday, October 17, 4:15-5:45 pm, Concurrent Platform Session B: 24. Variant Interpretation Practices and Resources Ballroom 20A #41-#46 25. Integrated Variant Analysis in Cancer Genomics Ballroom 20BC #47-#52 26. Gene Discovery and Functional Models of Neurological Disorders Ballroom 20D #53-#58 27. Whole Exome and Whole Genome Associations Room 6A #59-#64 28. Sequencing-based Diagnostics for Newborns and Infants Room 6B #65-#70 29. Omics Studies in Alzheimer's Disease Room 6C #71-#76 30. Cardiac, Valvular, and Vascular Disorders Room 6D #77-#82 31. Natural Selection and Human Phenotypes Room 6E #83-#88 32. Genetics of Cardiometabolic Traits Room 6F #89-#94 Wednesday, October 17, 6:00-7:00 pm, Concurrent Platform Session C: 33. -
Hst3 Is Turned Over by a Replication Stress-Responsive SCF Phospho
Hst3 is turned over by a replication stress-responsive SCFCdc4 phospho-degron Ellen R. Edenberga, Ajay A. Vashishtb, Benjamin R. Topacioa, James A. Wohlschlegelb, and David P. Toczyskia,1 aDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158; and bDepartment of Biological Chemistry, University of California, Los Angeles, CA 90095 Edited* by Stephen J. Elledge, Harvard Medical School, Boston, MA, and approved March 10, 2014 (received for review August 13, 2013) Hst3 is the histone deacetylase that removes histone H3K56 several E3 ubiquitin ligases to identify the one responsible for acetylation. H3K56 acetylation is a cell-cycle– and damage-regu- targeting Hst3 for degradation and found that Hst3 is partially lated chromatin marker, and proper regulation of H3K56 acetyla- stabilized at the nonpermissive temperature of temperature- tion is important for replication, genomic stability, chromatin sensitive mutants in CDC53 (the cullin scaffold for all SCF assembly, and the response to and recovery from DNA damage. ligases) and CDC4 (encoding an essential F-box protein) (Fig. Understanding the regulation of enzymes that regulate H3K56 1A). Inactivation of SCFCdc4 also stabilized Hst3 after treatment acetylation is of great interest, because the loss of H3K56 acetyla- B HST3 with hydroxyurea (HU) to induce replication stress (Fig. 1 ). tion leads to genomic instability. is controlled at both the Cdc4 transcriptional and posttranscriptional level. Here, we show that SCF recognizes its substrates through a phospho-degron – Hst3 is targeted for turnover by the ubiquitin ligase SCFCdc4 (20 22). To understand how Hst3 was targeted for turnover both after phosphorylation of a multisite degron. -
Structure of the Human Clamp Loader Reveals an Autoinhibited Conformation of a Substrate-Bound AAA+ Switch
Structure of the human clamp loader reveals an autoinhibited conformation of a substrate-bound AAA+ switch Christl Gaubitza,1, Xingchen Liua,b,1, Joseph Magrinoa,b, Nicholas P. Stonea, Jacob Landecka,b, Mark Hedglinc, and Brian A. Kelcha,2 aDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester MA 01605; bGraduate School of Biomedical Sciences, University of Massachusetts Medical School, Worcester MA 01605; and cDepartment of Chemistry, The Pennsylvania State University, University Park, PA 16802 Edited by Michael E. O’Donnell, HHMI and Rockefeller University, New York, NY, and approved July 27, 2020 (received for review April 20, 2020) DNA replication requires the sliding clamp, a ring-shaped protein areflexia syndrome (15), Hutchinson–Gilford progeria syn- complex that encircles DNA, where it acts as an essential cofactor drome (16), and in the replication of some viruses (17–19). It for DNA polymerases and other proteins. The sliding clamp needs is unknown whether loading by RFC contributes to PARD to be opened and installed onto DNA by a clamp loader ATPase of disease. the AAA+ family. The human clamp loader replication factor C Clamp loaders are members of the AAA+ family of ATPases (RFC) and sliding clamp proliferating cell nuclear antigen (PCNA) (ATPases associated with various cellular activities), a large are both essential and play critical roles in several diseases. De- protein family that uses the chemical energy of adenosine 5′- spite decades of study, no structure of human RFC has been re- triphosphate (ATP) to generate mechanical force (20). Most solved. Here, we report the structure of human RFC bound to AAA+ proteins form hexameric motors that use an undulating PCNA by cryogenic electron microscopy to an overall resolution ∼ spiral staircase mechanism to processively translocate a substrate of 3.4 Å. -
Identification and Characterization of a Novel Non-Homologous End Joining Factor MRI
Washington University in St. Louis Washington University Open Scholarship Arts & Sciences Electronic Theses and Dissertations Arts & Sciences Spring 5-15-2020 Identification and Characterization of a Novel Non-homologous End Joining Factor MRI Putzer Joseph Hung Washington University in St. Louis Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons, and the Medical Immunology Commons Recommended Citation Hung, Putzer Joseph, "Identification and Characterization of a Novel Non-homologous End Joining Factor MRI" (2020). Arts & Sciences Electronic Theses and Dissertations. 2201. https://openscholarship.wustl.edu/art_sci_etds/2201 This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. WASHINGTON UNIVERSITY IN ST. LOUIS Division of Biology and Biomedical Sciences Immunology Dissertation Examination Committee: Barry Sleckman, Chair Gaya Amarasinghe Brian Edelson Takeshi Egawa Nima Mosammaparast Kenneth Murphy Sheila Stewart Identification and Characterization of a Novel Non-homologous End Joining Factor MRI by Putzer Joseph Hung A dissertation presented to The Graduate School of Washington University in partial fulfillment of the requirements -
Watanabe S, Resch M, Lilyestrom W, Clark N
NIH Public Access Author Manuscript Biochim Biophys Acta. Author manuscript; available in PMC 2010 November 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Biochim Biophys Acta. 2010 ; 1799(5-6): 480±486. doi:10.1016/j.bbagrm.2010.01.009. Structural characterization of H3K56Q nucleosomes and nucleosomal arrays Shinya Watanabe1,*, Michael Resch2,*, Wayne Lilyestrom2, Nicholas Clark2, Jeffrey C. Hansen2, Craig Peterson1, and Karolin Luger2,3 1 Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation St.; Worcester, Massachusetts 01605 2 Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523-1870 3 Howard Hughes Medical Institute Abstract The posttranslational modification of histones is a key mechanism for the modulation of DNA accessibility. Acetylated lysine 56 in histone H3 is associated with nucleosome assembly during replication and DNA repair, and is thus likely to predominate in regions of chromatin containing nucleosome free regions. Here we show by x-ray crystallography that mutation of H3 lysine 56 to glutamine (to mimic acetylation) or glutamate (to cause a charge reversal) has no detectable effects on the structure of the nucleosome. At the level of higher order chromatin structure, the K to Q substitution has no effect on the folding of model nucleosomal arrays in cis, regardless of the degree of nucleosome density. In contrast, defects in array-array interactions in trans (‘oligomerization’) are selectively observed for mutant H3 lysine 56 arrays that contain nucleosome free regions. Our data suggests that H3K56 acetylation is one of the molecular mechanisms employed to keep chromatin with nucleosome free regions accessible to the DNA replication and repair machinery. -
Supplementary Materials
Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine -
Negative Breast Cancer Patients Without Germline BRCA1/2 Mutation
An 8-lncRNA signature predicts survival of triple- negative breast cancer patients without germline BRCA1/2 mutation Minling Liu The Seventh Aliated Hospital Sun Yat-sen University https://orcid.org/0000-0001-7317-5600 Wei Dai the aliated hospital of guangdong medical university Mengyuan Zhu The Seventh Aliated Hospital Sun Yat-sen University Xueying Li The Seventh Aliated Hospital Sun Yat-sen University Shan Huang The Seventh Aliated Hospital Sun Yat-sen University Min Wei The Seventh Aliated Hospital Sun Yat-sen University Lei Li ( [email protected] ) University of Hong Kong Shuo Fang ( [email protected] ) The Seventh Aliated Hospital Sun Yat-sen University Research article Keywords: long non-coding RNA, triple-negative breast cancer, germline BRCA1/2 mutation, overall survival Posted Date: August 28th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-66893/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/19 Abstract Background Triple-negative breast cancer (TNBC) is a particular breast cancer subtype with poor prognosis due to its aggressive biological behavior and strong heterogeneity. TNBC with germline BRCA1/2 mutation (gBRCAm) have higher sensitivity to DNA damaging agents including platinum-based chemotherapy and PARP inhibitors. But the treatment of TNBC without gBRCAm remains challenging. This study aimed to develop a long non-coding RNA (lncRNA) signature of TNBC patients without gBRCAm to improve risk stratication and optimize individualized treatment. Methods 98 TNBC patients without gBRCAm were acquired from The Cancer Genome Atlas (TCGA) database. The univariable Cox regression analysis and LASSO Cox regression model were applied to establish an lncRNA signature in the training cohort (N = 59). -
Systematic Screening Reveals a Role for BRCA1 in the Response to Transcription-Associated DNA Damage
Downloaded from genesdev.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press RESOURCE/METHODOLOGY Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage Sarah J. Hill,1,2 Thomas Rolland,1,2,3 Guillaume Adelmant,1,4,5 Xianfang Xia,1,2,3 Matthew S. Owen,1,2,3 Amelie Dricot,1,2,3 Travis I. Zack,1,6 Nidhi Sahni,1,2,3 Yves Jacob,1,2,3,7,8,9 Tong Hao,1,2,3 Kristine M. McKinney,1,2 Allison P. Clark,1,2 Deepak Reyon,10,11,12 Shengdar Q. Tsai,10,11,12 J. Keith Joung,10,11,12 Rameen Beroukhim,1,6,13 Jarrod A. Marto,1,4,5 Marc Vidal,1,2,3 Suzanne Gaudet,1,2,3 David E. Hill,1,2,3,14 and David M. Livingston1,2,14 1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; 2Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA; 3Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; 4Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA; 5Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; 6The Broad Institute, Cambridge, Massachusetts 02142, USA; 7Departement de Virologie, Unite de Gen etique Moleculaire des Virus a ARN, Institut Pasteur, F-75015 Paris, France; 8UMR3569, Centre National de la Recherche Scientifique, F-75015 Paris, France; 9UnitedeG en etique Moleculaire des Virus a ARN, Universite Paris Diderot, F-75015 Paris, France; 10Molecular Pathology Unit, Center for Computational and Integrative Biology, 11Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA; 12Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA; 13Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA BRCA1 is a breast and ovarian tumor suppressor.